Beck Bode LLC Has $2.05 Million Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

Beck Bode LLC grew its position in Royalty Pharma plc (NASDAQ:RPRX) by 0.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 73,042 shares of the biopharmaceutical company’s stock after buying an additional 464 shares during the quarter. Beck Bode LLC’s holdings in Royalty Pharma were worth $2,052,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Allworth Financial LP lifted its position in shares of Royalty Pharma by 89.8% in the third quarter. Allworth Financial LP now owns 953 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 451 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Royalty Pharma by 112.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,005 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 531 shares in the last quarter. Lindbrook Capital LLC lifted its position in shares of Royalty Pharma by 485.2% in the fourth quarter. Lindbrook Capital LLC now owns 2,411 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 1,999 shares in the last quarter. Rakuten Securities Inc. purchased a new stake in shares of Royalty Pharma in the fourth quarter worth approximately $110,000. Finally, CWM LLC lifted its position in shares of Royalty Pharma by 75.9% in the third quarter. CWM LLC now owns 4,782 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 2,064 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

RPRX has been the subject of a number of research analyst reports. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, April 11th. Bank of America cut their price objective on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating on the stock in a research report on Friday, April 12th. JPMorgan Chase & Co. cut their price objective on shares of Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 20th. Finally, The Goldman Sachs Group cut their price objective on shares of Royalty Pharma from $56.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, February 20th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $46.75.

Royalty Pharma Stock Performance

Shares of Royalty Pharma stock traded down $0.42 on Tuesday, reaching $27.70. The stock had a trading volume of 2,630,831 shares, compared to its average volume of 2,669,299. The business’s 50-day moving average price is $29.52 and its two-hundred day moving average price is $28.58. The company has a debt-to-equity ratio of 0.61, a quick ratio of 7.90 and a current ratio of 7.90. Royalty Pharma plc has a fifty-two week low of $25.92 and a fifty-two week high of $35.76. The stock has a market cap of $16.55 billion, a P/E ratio of 14.66 and a beta of 0.45.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.12. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. The business had revenue of $736.00 million during the quarter, compared to analysts’ expectations of $702.90 million. On average, sell-side analysts forecast that Royalty Pharma plc will post 3.95 EPS for the current year.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 17th will be paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.03%. The ex-dividend date of this dividend is Thursday, May 16th. Royalty Pharma’s payout ratio is 44.44%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.